CN106178163A - Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument - Google Patents
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument Download PDFInfo
- Publication number
- CN106178163A CN106178163A CN201610541000.1A CN201610541000A CN106178163A CN 106178163 A CN106178163 A CN 106178163A CN 201610541000 A CN201610541000 A CN 201610541000A CN 106178163 A CN106178163 A CN 106178163A
- Authority
- CN
- China
- Prior art keywords
- cell
- blood
- hiv
- aids
- separator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 95
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 38
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 26
- 230000003053 immunization Effects 0.000 title claims abstract description 24
- 238000002649 immunization Methods 0.000 title claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims abstract description 280
- 210000004369 blood Anatomy 0.000 claims abstract description 104
- 239000008280 blood Substances 0.000 claims abstract description 104
- 210000002381 plasma Anatomy 0.000 claims abstract description 95
- 210000002540 macrophage Anatomy 0.000 claims abstract description 85
- 239000007788 liquid Substances 0.000 claims abstract description 55
- 239000000463 material Substances 0.000 claims abstract description 21
- 230000004087 circulation Effects 0.000 claims abstract description 18
- 210000000601 blood cell Anatomy 0.000 claims abstract description 15
- 230000010412 perfusion Effects 0.000 claims abstract description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 210000005087 mononuclear cell Anatomy 0.000 claims description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 13
- 229960002897 heparin Drugs 0.000 claims description 13
- 229920000669 heparin Polymers 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 108010041397 CD4 Antigens Proteins 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 230000008676 import Effects 0.000 claims description 6
- 239000004744 fabric Substances 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 241000605008 Spirillum Species 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 238000004132 cross linking Methods 0.000 claims description 3
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 108700020796 Oncogene Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 238000012412 chemical coupling Methods 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 210000004332 phalangeal cell Anatomy 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 238000002360 preparation method Methods 0.000 abstract description 19
- 238000000746 purification Methods 0.000 abstract description 19
- 206010057249 Phagocytosis Diseases 0.000 abstract description 16
- 230000008782 phagocytosis Effects 0.000 abstract description 16
- 230000003321 amplification Effects 0.000 abstract description 15
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 15
- 210000003677 hemocyte Anatomy 0.000 abstract description 11
- 229940000351 hemocyte Drugs 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000000242 pagocytic effect Effects 0.000 abstract description 5
- 238000012761 co-transfection Methods 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 109
- 108020004414 DNA Proteins 0.000 description 34
- 238000000034 method Methods 0.000 description 33
- 210000000265 leukocyte Anatomy 0.000 description 27
- 239000000872 buffer Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 22
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 238000001514 detection method Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 20
- 238000011534 incubation Methods 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 238000001556 precipitation Methods 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 239000006285 cell suspension Substances 0.000 description 17
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 16
- 241000700605 Viruses Species 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 15
- 230000006870 function Effects 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000012531 culture fluid Substances 0.000 description 14
- 230000012010 growth Effects 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 210000003714 granulocyte Anatomy 0.000 description 12
- 230000001464 adherent effect Effects 0.000 description 11
- 238000001816 cooling Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000023555 blood coagulation Effects 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000003448 neutrophilic effect Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004970 cd4 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005138 cryopreservation Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229960004756 ethanol Drugs 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 5
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- -1 intergrase Proteins 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101710128836 Large T antigen Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 229920006221 acetate fiber Polymers 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000003701 histiocyte Anatomy 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102100022133 Complement C3 Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 210000004381 amniotic fluid Anatomy 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000010100 anticoagulation Effects 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000003547 immunosorbent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 235000010585 Ammi visnaga Nutrition 0.000 description 2
- 244000153158 Ammi visnaga Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101710114816 Gene 41 protein Proteins 0.000 description 2
- 208000031957 HIV carrier Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000035485 pulse pressure Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013022 venting Methods 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 102000018348 CC chemokine receptor 5 Human genes 0.000 description 1
- 108010017088 CCR5 Receptors Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000015612 Complement 3b Receptors Human genes 0.000 description 1
- 108010024114 Complement 3b Receptors Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000702463 Geminiviridae Species 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
- 229940122440 HIV protease inhibitor Drugs 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 101150050863 T gene Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000005167 amoeboid movement Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BNKJLPZCWJJFDW-UHFFFAOYSA-N butyl 2-methylprop-2-enoate 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound CCCCOC(=O)C(C)=C.C[N+](C)(C)CCOP(O)([O-])=O BNKJLPZCWJJFDW-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000000250 cementoblast Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000002986 dental sac Anatomy 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 201000003373 familial cold autoinflammatory syndrome 3 Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 239000003084 hiv integrase inhibitor Substances 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000000680 phagosome Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3692—Washing or rinsing blood or blood constituents
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
nullA kind of acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument for medical domain,It is characterized in that preparation can separated plasma、Mononuclear blood cell and the blood of multinucleated giant cell formed because living away from home HIV and plasma separator,Build SV40LTag pcDNA3.1 () and pLXSNneo hTERT recon,Macrophage immortalization is caused through co-transfection,Cells frozen storing liquid it is formulated in after amplification,Cell concentration is made to reach 80%,Then the depurator that perfusion macromolecular material is made,Macrophage strain therein plays the effect of phagocytosis HIV,Depurator and blood、Plasma separator constitutes crucial extracorporeal circulation apparatus,When blood flows through blood separator,Multinucleated giant cell containing HIV is filtered out,And then the blood plasma separated by plasma separator is when flowing through depurator,HIV therein is by macrophage phagocytic,The mononuclear blood cell that blood plasma after purification is separated with plasma separator feeds back after converging,Thus reach to remove in hemocyte、The purification treatment purpose of outer HIV.
Description
Technical field
The present invention relates to preparation and the application of acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument in medical domain, be mainly used in AIDS
The removing of the inside and outside HIV (human immunodeficiency virus) of patient's hemocyte, thus reach to treat the purpose of acquired immune deficiency syndrome (AIDS).
Background technology
Acquired immune deficiency syndrome (AIDS) is the biography caused by HIV (human immunodeficiency virus) (Human Immunodeficiency Virus, HIV)
Catch an illness, be widely current in the whole world, according to World Health Organization (WHO) (WHO) and the relevant report of UNAIDS, from
Since within 1981, the U.S. finds Patient With Aids case, the whole world has 208 countries and regions to receive the serious of acquired immune deficiency syndrome (AIDS) so far
Threatening, there are about 40,000,000 people and infected acquired immune deficiency syndrome (AIDS), death toll is more than 20,000,000, and there are about 6000 people every day becomes acquired immune deficiency syndrome (AIDS) sense
Dye person, there are about people more than 300 simultaneously every day and dies from acquired immune deficiency syndrome (AIDS).It is in rapid growth period at HIV infected individuals in China, super
Cross 1,000,000.Acquired immune deficiency syndrome (AIDS) has become as the great of after tumor, cardiovascular and cerebrovascular disease, tuberculosis, diabetes another facing mankind
Infectious disease, it has also become the serious public health of global concern and social problem.
HIV (human immunodeficiency virus) is a kind of slow virus (Lentivirus) infecting human immune cells, belongs to reverse transcription sick
The one of poison, diameter about 120 nanometer, the most spherical in shape.Outer virionic membrane is lipoid peplos (from host cell), and is embedded with virus
Albumen gp120 and gp41.Gp41 is transmembrane protein, and gp120 is positioned at surface, and is combined by noncovalent interaction with gp41.To
It is inside the sphere matrix (Matrix) formed by albumen p17, and the half-cone capsid (Capsid) that albumen p24 is formed, capsid
In high electron density under Electronic Speculum, include virulent rna gene group, enzyme (reverse transcriptase, intergrase, protease) and other
Composition from host cell.
After HIV enters human body, first by macrophage phagocytic, but HIV quickly changes macrophage some position interior
Sour environment, creates the condition of its existence applicable, is not the most killed and the most within it breeds.Because CD4 is being subject to of HIV
Body, thus in macrophage breeding HIV by its envelope protein gp120 and under the auxiliary of gp41, (gp41 plays bridge
Effect, utilizes self hydrophobic interaction mediate retroviral cyst membrane and cell membrane fusion) (cell, monokaryon are huge to be bitten carefully to enter CD4+ cell
Born of the same parents, dendritic cell etc.), in intracellular rapid propagation, produce 10 every day9~1010Virion, and it is normal constantly to enter other
And regeneration the intracellular duplication of CD4+, manufacture more virus infected cell, make peripheral blood CD4+T cell sustaining breakdown, subtract
Few.Gp120 with the CD4 receptor of HIV be combined can directly activate infected apoptosis, even infected by HIV T cell express
Envelope antigen also can start normal T-cell, indirectly causes a large amount of broken of CD4+ cell by the crosslinking of cell surface CD4 molecule
Bad, result causes the severe immune deficiency centered by CD4+T cell defect, and patient mainly shows: periphery lymphocyte reduces,
T4/T8 proportional arrangement, to phytohaemagglutinin and the loss for reaction of some antigen, delayed allergy declines, and NK cell, huge bites
Cytoactive weakens, and the synthesis of the cytokine such as IL2, IFN-γ reduces.CD4+T cell is most important immunocyte, infects
Person once loses a large amount of CD4+T cell, and whole immune system will suffer deathblow, and the infection to various diseases is all lost
Go resistance.HIV can also show as hiding for a long time and not showing clinical symptoms after entering host's CD4+ cell, its genome
RNA reverse transcription becomes double-stranded DNA, enters in host cell core with viral integrase enzyme, and under the effect of intergrase, double-stranded DNA is integrated
In host cell gene group, integrated viral DNA is referred to as provirus, and the several months of can hiding does not replicates, and causes
The AIDS several months is to incubation period for many years.In the incubation period of AIDS, HIV is mainly in the macrophage and dendritic cell of lymph node
Breeding, these cells are internal HIV depots, releasably to peripheral blood or transfection peripheral blood in CD4+T cell, have silk to divide
Splitting former, antigen, TNF, IL-2 and lymph element (LT) can excite HIV provirus gene multiple at the CD4+T Intracellular transcription infected
System.After a large amount of propagation, inhibition of HIV granule constantly discharges from destroyed infection cell and is free on blood, then enters back into
Other cells continue course of infection.
Body can be stimulated after HIV to produce envelope protein (Gp120, Gp41) antibody and core protein (P24) antibody.?
Measuring low-level antiviral neutralizing antibody in HIV carriers, AIDS patients serum, wherein AIDS patients level is minimum,
HIV carriers are the highest, and the most protected effect of this antibody is described.But antibody can not be with the virus that retains in mononuclear phagocyte
Contacting, and HIV envelope protein easily occurs antigenic variation, original antibody is ineffective, makes neutralizing antibody not play due
Effect.In the latent infection stage, HIV provirus is integrated in host cell gene group, and therefore HIV will not be known by immune system
Not, so only relying on autoimmune function and cannot being removed.The critically important reason of another one should be to kill according to antibody
Go out, remove antigen mechanism speculate, after immune antibody is combined with antigen, if immunological effect to be produced, or pass through activation
Complement, mediation ADCC effect dissolves cellular antigen, but HIV is not cellular antigen;Phagocytosis is attracted by chemotaxis
Antigen is removed in cell phagocytosis, but HIV is protected in phagocyte on the contrary, breeds;Antibody has been combined neutralization and has made with antigen
With, it is allowed to lose appeal, but HIV antigenic structure is changeable, often make antibody be difficult to.
In terms of the treating AIDS method having been used for clinic at present, effect is less preferable: (1) hiv reverse transcriptase suppresses
Agent: be only capable of preventing the permissive cell of not yet infected by HIV from infecting, the cell infected do not had therapeutical effect, and toxic and side effects is relatively
Many, including gland plastochondria toxicity, bone marrow depression, globular anemia, granulocyte and thrombocytopenia, pancreatitis, intersect resistance in addition
The generation of the property of medicine, this kind of medicine is not used alone, and mainly does drug combination, and is easily generated drug resistance mutant, causes under clinical efficacy
Fall or inefficacy.(2) hiv protease inhibitor: be easily generated the toxic and side effects such as drug induced hepatic injury, lipid metabolic disorder and drug resistance
Property.(3) hiv integrase inhibitor: integrated with host cell DNA by suppression inhibition of HIV DNA and play a role, reverse with HIV
Transcriptase inhibitors and protease inhibitor associating use simultaneously and antiviral are had synergism.(4) suppression inhibition of HIV enters suppression
Agent: include block gp120 with CD4 be combined, block HIV be combined with accessory receptor, act on gp41 film subunit and act on T pouring
Bar cell surface CC-chemokine receptor 5 (CCR5) blocks HIV and enters host cell, but liver and heart are had side effect.(5)
Cytokine therapy: be mainly used in regulatory T-cell dynamic equilibrium.(6) HIV vaccine treatment: due to the particularity of HIV, as intrinsic
Immunity is not enough to resist HIV and targeting destroys immune system, and virus mutation is rapid, causes the most not yet developing real safety
Effective vaccine.(7) gene therapy: the research of HIV gene therapy is never interrupted, does including antisense technology, RNA bait, RNA
Disturb, intrabody, dominant negative mutant, suicide gene etc., but enter the II clinical trial phase stage gene therapy almost
No.(8) monoclonal antibody passive immunization therapy: reduce the susceptibility of HIV by lowering CD4+T cell surface CCR5, prolong
The progress of slow acquired immune deficiency syndrome (AIDS) and the diffusion of minimizing HIV, neutralizing monoclonal antibody 2G12,2F5 and 4E10 are applied to HIV person to be had
Good toleration and safety, can delay but can not stop virus bounce-back (9) adoptive immunity cell therapy: external in a large number
Virus a large amount of amplification can be caused when cultivating CD4+T cell autologous for HIV, increase the CD4+T cell quantity that virus infects, and feed back
CD4+T cell may increase the place of internal virus replication, causes virus load to rebound, and on the whole, adoptive immunity is thin
Born of the same parents treat without obvious toxic and side effects, also do not obtain satisfied therapeutic effect.
The phagocyte of the mankind has large and small two kinds, and microphage is the neutrophilic granulocyte in peripheral blood, macrophagocyte
Being the mononuclear cell in blood and the macrophage in multiple organ, tissue, both constitute mononuclear phagocyte system.Mononuclear cell
Formed by the monocyte precursor Development And Differentiation in bone marrow, account for the 3%-8% of blood middle leukocytes sum, its volume relatively lymph
Cell is bigger, and mononuclear cell the most only stops 12-24 hour, subsequently into connective tissue or organ, reaches maturity as huge
Phagocyte, macrophage is the differentiation of mononuclear phagocyte system camber, ripe cell type, has stronger phagocytosis merit
Can, wandering macrophage is more than mononuclear cell several times, lasts a long time, some months of can surviving in the tissue, the macrophage settled down
Having different titles, be Kupffer Cell, be microglia in brain, be osteoclast etc. in bone in liver, it expresses Fc
Receptor, C3b receptor and CDl4, play defense function in inherent immunity, is also that the professional antigen participating in adaptive immunity is offered
Cell.The CD4 molecule of Expression of Macrophages, is the receptor of HIV (human immunodeficiency virus) (HIV), after HIV enters human body, first suffers huge biting carefully
The phagocytosis of born of the same parents, but HIV quickly changes the sour environment at macrophage some position interior, creates condition of its existence applicable,
The most it is not killed amount reproduction the most within it to assemble, then HIV is passed to CD4+T cell.
Having document to report, simian virus 40 (SV40) can make some human cell that immortalization occurs.Poulin DL、
The research such as Kung AL and Sullivan CS shows, the importing of SV40LT antigen gene can accelerate to convert the growth rate of cell,
After immortalized cells the most repeatedly passes on, still there is metastable multiplication characteristic and functional status, also can retain it simultaneously
Many phenotypic differentiations of germinal cell, may be used for the foundation of the some kinds of cell model of human and animal.Also there is document report
Road, imports exogenous hTERT and cell can be made to keep normal phenotype and differentiating characteristic, the most utilized hTERT to be successfully established
The immortalized cell line of some cell, keeps that chromosome stabilityX, differentiation be normal, contact inhibition, relative without oncogenicity etc. substantially
The growth characteristics of " normally ", in stomatology field, Japanese scholars Kamata, Fujita and Fujii transfection hTERT establishes forever
Biochemical people's Gingival Fibroblasts, periodontal cell, pulp cells system and Dental Follicle Cells system, cell population doublings number reach 150 times with
On, cell all shows original biological characteristics, can express the associated protein of derived cell, Kitagawa after inducing culture
Establishing people cementoblast system Deng transfection hTERT, cell multiplication reaches more than 200 times, cell differentiation mark such as alkalescence phosphorus
Acid enzyme, type i collagen etc. are expressed stable.Recent research proves, simian virus 40 (SV40) can make some human cell occur
Immortalization, can make cell tide over M1 after date and continue survival, Secondary Culture 20-30 generation, and then cell can enter again climacteric (M2
Phase), cell mortality increases and accompanies chromosomal abnormality, and the cell of division gradually decreases, most cell death, and
HTERT can maintain stablizing of cell chromosome telomere, so that cell is tided over a crisis the phase (M2 phase), can continue survival, pass on
Reach 100-300 generation more than, so setting up immortalized cell line, SV40 with SV40 and hTERT transfected with human in vitro tissue cell simultaneously
Cell can be made to tide over the M1 phase, and hTERT can make cell tide over the M2 phase, and than being used alone, one of them cell line set up is more steady
Calmly, the life-span is longer.
But have no based on the gene constructed macrophage system of SV40LT and/or hTERT and then expand for acquired immune deficiency syndrome (AIDS) in a large number
The report for the treatment of.
Summary of the invention
In order to solve to attack for a long time the global problem in the treating AIDS field being unable to, present inventors have proposed the present invention.
The invention aims to provide acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument;Another object is intended to provide AIDS diease occurrence
The preparation of thing cellular immunotherapy instrument and application process.
The object of the present invention is achieved like this: it is thin that preparation can filter the large volume containing HIV that many cells are combined into
The blood separator of born of the same parents and can separate the plasma separator of mononuclear blood cell and blood plasma, prepares and connects through BamHI enzyme with T4 DNA
Cut plasmid SV40LTag DNA and carrier pcDNA3.1 (-) product of DNA and build SV40LTag-pcDNA3.1 (-) restructuring
Son and with Ligation Mix connect through EcoR I's and Xho I double digestion plasmid pCIneo-hTERT and carrier pLXSNneo
Product and the pLXSNneo-hTERT recon that builds, and then cause its immortalization with liposome co-transfection macrophage, through expanding
Being formulated in cells frozen storing liquid after increasing, make cell concentration reach 80%, preventing that then perfusion high-biocompatibility material is made is thin
Born of the same parents and fragment thereof leach and can provide the depurator in place for macrophage phagocytic HIV, and wherein macrophage strain is fixed on only
Change in device and play phagocytosis HIV and be used, made depurator so that with blood, plasma separator combination additional computer regulatory process and
Preparation acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument, the blood separator that the blood in extracorporeal circulation is treated in instrument filters large volume
Multinucleated giant cell, be divided into blood plasma and mononuclear blood cell by plasma separator, the purified device of blood plasma is removed after HIV thin with single blood
Born of the same parents feed back after converging.
The present invention is made up of blood separator, plasma separator and depurator, wherein the aperture of blood separator be 150~
250 μm, 50~150 μm, 15~40 μm, 8~15 μm, 5~8 μm, 3~5 μm, 1~2 μm, can filter HIV cell in blood
The multinucleated giant cell formed or many cells polymer, plasma separator can separate mononuclear blood cell and the blood plasma of medium volume, blood
Cleanser in slurry depurator is macrophage strain, is easy to prolonged cold and saves backup, bite because of huge after being formulated in cells frozen storing liquid
The CD4 molecule that cell is expressed is the receptor of HIV (human immunodeficiency virus), has the characteristic of natural phagocytosis HIV, and the present invention simulates macrophage and exists
The pattern of internal non-specific phagocytosis, when the blood plasma containing HIV flows through depurator, HIV and macrophage come in contact and quilt
Phagocytosis, is detained in depurator therewith, so in the extracorporeal circulation of acquired immune deficiency syndrome (AIDS) plasma purification treatment, containing a large amount of HIV's
First large volume cell is filtered by blood separator, and HIV free in blood plasma is cleaned device and removes, the blood plasma after purification with in
Isopyknic mononuclear blood cell feeds back after converging, thus removes and be combined in cell surface and/or intracellular HIV and be free on
The HIV of blood plasma.The routine that the present invention cannot effectively kill HIV for a long time with the method replacement of the external HIV of filtering is internal degeneration-resistant
Transcribe drug treatment.
Detailed description of the invention
Fig. 1 is the application schematic diagram of the acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument proposed according to the present invention.
Fig. 2 is the internal structure schematic diagram of the blood separator proposed according to the present invention.
Fig. 3 is the internal structure schematic diagram of the plasma separator proposed according to the present invention.
Fig. 4 is the internal structure schematic diagram of the depurator proposed according to the present invention.
In Fig. 1, one end of arterial blood line pipe (1) is connected with arteries, the other end through heparin and blood pump (2) with contain
The blood separator (3) having waste liquid outlet (5) is connected, and blood separator (3) exports (4), blood pump (6), circulation pipe through blood
Road (7) is connected with plasma separator (8), the plasma outlet port of plasma separator (8) through blood plasma pump (9) and blood vessel (10) with two
Depurator (11) in parallel is connected with depurator (12), the export pipeline (13) of two depurators and the blood of plasma separator (8)
Cell outlet pipeline (14) circulates through venous line (15) fluid confluence after converging.
Fig. 2 represents the internal structure of the blood separator (3) in Fig. 1.In Fig. 2, the tube wall of the inner chamber (2) of separator (1)
On have a lot of micropore (3), multinucleated giant cell (4) micropore (3) can not be filtered and be delayed at inner chamber (2), thus can be eliminated, energy
By in micropore (3), the mononuclear blood cell (5) of small size enter exocoel (6), then flow out through outlet (7), and then through Fig. 1
Shown plasma separator (8) isolates hemocyte and blood plasma.
Fig. 3 represents the internal structure of the plasma separator (8) in Fig. 1.In Fig. 3,1 is plasma separator, and 2 is that blood plasma separates
Device inner chamber, 3 is the micropore on plasma separator inner chamber tube wall, and 4 is the mononuclear blood cell that can not pass through micropore (3), and 5 is to pass through
The blood plasma chemical analysis of micropore (3), 6 is plasma separator exocoel, and 7 is blood plasma flow export, and 8 is that to have the blood of switchable valve thin
Born of the same parents export.
In Fig. 4,1 is depurator, and 2 is the macrophage strain in depurator;3 is the HIV entering depurator together with blood plasma,
The phagosome no longer moved down after the phagocyte phagocytosis that 4 are cleaned in device for HIV, the macrophage that 5 is macrophage generation because of
Son.
Below in conjunction with Fig. 1, Fig. 2, Fig. 3 and Fig. 4, the enforcement to the acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument that the present invention proposes
Scheme is explained in detail.
One, macrophage strain is built
(1) sorting macrophage
1, primary cell is gathered
(1) single core blood cell is gathered: refer to lymphocyte and the monokaryon separated from blood with density-gradient centrifuga-tion method
Macrophage.Concrete grammar is: the White Blood Cells Concentrate buying Blood Center or the Cord blood preserved for scientific research, takes 2mL specimen,
6mL anticoagulation dropper, by hemodilution 2~3 times, is fully slowly superimposed on along tube wall after mixing and has added 4mL and drench by PBS liquid
Horizontal centrifugal (400r/min, 20 DEG C) 35min in horizontal centrifuge in the 10mL centrifuge tube of bar cell separation liquid;After Li Xin in pipe
Being divided into 3 layers, upper strata is blood plasma and PBS liquid, and lower floor is mainly erythrocyte and granulocyte, and middle level is lymphocyte separation medium, upper,
Interface, middle level has the white cloud and mist layer narrow band based on mononuclearcell to be PBMC, is inserted into cloud and mist layer with capillary pipette,
Draw PBMC and insert in another 50mL centrifuge tube, add 5 times and be centrifuged (300r/min, 20 DEG C) 10min with upper volume PBS, abandon
Clear 50mLPBS re-suspended cell, centrifugal (350r/min, 20 DEG C) 15min, abandons supernatant, adds Buffer (PBS+0.5% new born bovine
Serum+2mmol/LEDTA, pH7.2) 2mL re-suspended cell, take 15uL cell suspension and add counted under microscope on blood counting chamber
Cell (PBMC) sum in 4 block plaid.(2) single core histiocyte is gathered: by Zhejiang University's Tissue Engineering Study platform
There is provided.Substantially belonging to the macrophage from spleen, its preparation method is: the 1. acquisition of spleen tissue and transhipment: normally
Under committee's approval and patient's informed consent, take the spleen specimen tissue of excision, shred into volume about 1mm immediately3Little
Piece of tissue, moves in the sterile sealing bottle equipped with pre-cooling 4 DEG C, is transported to rapidly cell culture chamber.2. spleen tissue cell suspension
The preparation of liquid: spleen tissue block moves to aseptic operating platform, PBS washs 3 times, and RPMI-1640 washs 2 times, to remove in tissue
Blood and ensure the aseptic of tissue.Mechanical lapping spleen tissue, the most just has substantial amounts of histiocyte to hang and is mixed in RPMI-1640
In liquid.Filtering to hang with 200 mesh stainless steel filtering nets and be mixed with histiocytic RPMI-1640 liquid, filtrate is spleen tissue cell suspension
Liquid (mainly containing erythrocyte, lymphocyte, macrophage etc.).3. erythrocytic cracking in spleen tissue cell suspension: then
Centrifugal (1000r/min, 3min) with the washing of RPMI-1640 liquid, to remove cell debris, add Tris-NH4Cl effect 5min,
Splitting erythrocyte, Quick spin (1000r/min, 3min), remove the splitting erythrocyte fragment in supernatant, PBS washing centrifugal 3
Secondary, centrifugal 1 time of RPMI-1640 washing, to remove the Tris-NH4Cl of remaining in suspension, it is to avoid it affects the survival of cell,
Now, main containing spleen tissue macrophage and lymphocyte in suspension.4. the adhere-wall culture of spleen tissue macrophage: will
Aforementioned suspension is as cultivating cell stock solution, and Trypan Blue judges vigor and counts, and adjusts cell concentration with RPMI-1640 liquid
For (3~5) × 106/ L, will adjust the cell suspension inoculation of concentration in glass culture bottle, and condition of culture is 37 DEG C, 50mL/
LCO2, 100% humidity, cultivate 2~3h respectively, under phase contrast microscope, observe form.The digestion of adherent spleen tissue macrophage:
The digestion of adherent spleen tissue macrophage: suck culture supernatant, macrophage is adherent, and PBS repeatedly blows and beats, digests, gained
Cell suspension washing is centrifugal (1000r/min, 3min), obtains isolated and purified macrophage.Further, it is also possible to take treatment or hands
Postoperative discarded specimen extracts preparation, such as peritoneal cavity liquid, alveolar, liver, spleen, peritoneal tissues, small intestinal mucosa etc..(3) gather
Amniotic fluid, villus cell: attached hospital for obstetrics and gynaecology of Zhejiang University reproduction genetic laboratory is standby.The approval of reason committee and patient
Under informed consent, treating excess syndrome tests the residue amniotic fluid after diagnosis report, villus cell, selects exponential phase cell to continue to employ.
2, sorting attached cell (the preliminary adherent sorting of macrophage)
Cell is cultivated routinely, but according to the difference of cellularity, suitably adjusts incubation time, condition of culture etc., typically
Single core blood cell (PBMC) or single core histiocyte (macrophage) are placed in containing RPMI-1640 culture medium by adherent method
Culture dish in, in 37 DEG C, 5%CO2Cell culture incubator (Themo electro corporation CLASS 100, beautiful
State) in hatch 2h, after mononuclearcell is adherent, inhale abandon upper strata suspension cell (cell beyond macrophage be difficult to adherent and
Remove with upper liquid), PBs buffer washs 3 times gently, adds a small amount of RPMI-1640 culture medium, scrapes with cell scraper adherent
Cell (predominantly macrophage, but also have other attached cells a small amount of).1 000r/min is centrifuged 5min, abandons supernatant.Amniotic fluid is thin
Born of the same parents, villus cell are cultivated 1~7 day, occur that cell growth clone, cell growth converge rate and reach the exponential phase of 60~80%
Cell, with trypsinization, PBS, obtains cell suspension, is made into proper cell concentration.
3, sorting cd4 cell
Employing immunomagnetic beads method sorting cd4 cell: 1. main agents and instrument: (Germany U.S. sky Ni is biological for CD4 immunomagnetic beads
Technology Co., Ltd.);0.2% Trypan Blue liquid (Shanghai Sheng Gong biotechnology service company);New-born calf serum
(Hyclone company);MiniMACS magnetic separation system (Mei Tian Ni Bioisystech Co., Ltd of Germany).2. cd4 cell immunity
Magnetic bead sorting method: cell suspension is divided equally to two 1.5mLEppendorf pipes, centrifugal (300r/min, 20 DEG C) 10min, discards
Supernatant, the every 80uLBuffer of re-suspended cell contains cell number 107Individual, every 107Individual cell add 20uLCD4MicroBeads or
CD8MicroBeads, fully mixes, and hatches 15min at 4~8 DEG C, uses 1mLBuffer washed cell, centrifugal (300r/min, 20
DEG C) 10min, supernatant discarded 500uLBuffer re-suspended cell, MS detached dowel is placed in the magnetic field of MACS separator, with
500uLBuffer rinses, and by 500uL cell suspension by detached dowel, rinses detached dowel repetitive operation 3 times with 500uLBuffer,
Collect effluent, containing non-cd4 cell in effluent, in separator, take out detached dowel, divide with 1000uLBuffer pressure flush
From post, collecting effluent, this is that (cell viability detects cd4 cell: takes 15uL cell suspension before and after cell purification respectively and waits body
Long-pending trypan blue solution mixing, the not colored shinny person of basis of microscopic observation is living cells, and the coloring person of swelling is dead cell, calculates 200
The percentage ratio of living cells in individual cell).The cell now sorted is mainly macrophage.
4, sorting CDl4 cell (sorting macrophage)
CDl4 is mononuclear cell and the distinctive surface marker of macrophage, if in theory from single core histiocyte, sheep
Sort in water cell and villus cell, then gained cell is macrophage;If sorted from single core blood cell, then gained
Cell includes mononuclear cell and macrophage;But because the mononuclear cell life-span is short, only survives 1 day in peripheral blood and can not show a candle to huge biting
Cell is prone to adherent growth, so the most substantially removing in the cell attachment of the present invention is cultivated, the cell sorted out is essentially
Macrophage.
Basic skills is analogous to cd4 cell, uses immunomagnetic beads method.1. reagent: people's CDl4 immunomagnetic beads test kit
(Miltenyi Biotec, Germany), RPMI-1640 culture medium (Hyclone, the U.S.);2. immunomagnetic beads method: (A) magnetic bead is with special
Opposite sex target cell one mononuclear cell combines: every 1 × 108Individual PBMC adds magnetic bead and the 800uL buffering of 200uL coupling CDl4 antibody
Liquid (containing the bovine serum albumin 2.5mL and 2mol/L EDTA0.5mL of 10%, 4 DEG C of refrigerator pre-coolings), in 15mL centrifuge tube
Fully mixing, hatches 15min for 4 DEG C, and centre can slightly shake 1 time.Taking-up centrifuge tube after 15min, every 1 × 107Individual cell adds 1
~2mL pre-cooling buffer, 1 000r/min, centrifugal 8min, abandon supernatant, add 0.5mL buffer and blow and beat into single cell suspension.
(B) collect the mononuclear cell of marked by magnetic bead: be placed on MACS magnetic frame by cell separation post, add 1mL buffer statocyte
Detached dowel, treats that no liquid is dripped, and is added by above-mentioned cell suspension in people's cell separation post immediately, with 0.5mL wash buffer cell
Detached dowel 3 times.After to be rinsed, add 1mL buffer, emigrated cells detached dowel from magnetic frame, quickly promote with pin post,
Go out the cell combined with CDl4 antibody one magnetic bead in detached dowel, be the macrophage of CDl4+.
Additionally, following 2 kinds of methods sorting also can be used, including 1. adherent method: be placed in by PBMC and cultivate containing RPMI-1640
In the culture dish of base, in 37 DEG C, containing 5%CO: cell culture incubator (Themo electro corporation CLASS 100,
The U.S.) in hatch 2h.After adherent mononuclear cells, inhaling and abandon upper strata suspension cell, PBs buffer washs 3 times gently, adds a small amount of
RPMI-1640 culture medium, scrapes attached cell with cell scraper.1 000r/min is centrifuged 5min, abandons supernatant.2. flow cytometry
Method: CDl4 labelling: take PBMC, adjusts with buffer (bovine serum albumin 2.5mL and 2mol/LEDTA 0.5mL containing 10%)
Whole cell density is 1 × 108/ mL, adds CDl4+-FITC antibody 100uL, 4 DEG C of lucifuge labellings in every milliliter of cell suspension
18min, then addition 1mL streaming buffer is to terminate dyeing in centrifuge tube, PBs washs 3 times, with the PBS containing 2% mycillin
Adjustment cell density is 2 × 107/mL.Selected by flow cytometry apoptosis: by the cell of preparation at flow cytometer (BD FAcsAria
II, U.S.) upper sorting, according to the fluorescence intensity of CDl4 antibody, the relative size of cell and the relative particle of cell and interior
The complexity of portion's structure, collects CDl4+ cell (macrophage) standby.
(2) SV40LT/pcDNA3.1 and hTERT/pLXSNneo recon is built
1, SV40LT and hTERT gene is extracted
(1) extraction of SV40LT and hTERT: (I) enzyme action SV40LT and hTERT: 1. enzyme action SV40LT: contain from commercially available purchase
There are SV40 freeze dried powder or the SV40 plasmid of large T antigen gene, are dissolved in appropriate H2In O or TE buffer, add 2uL10 × enzyme
Cut buffer, 18uL H2O and restricted enzyme BamH I (1-5U/ugDNA), 37 DEG C of incubation 1h, 75 DEG C of heating 15min, go out
Live enzyme, add 5uL electrophoresis sample loading buffer (also can by add 0.5mol/L EDTA) and terminate reaction in case electrophoresis.2. enzyme action
HTERT:hTERT between EcoRI and the SalI site of plasmid pClneo-hTERT, pLXSNneo vector multiple cloning site
(MCS) restriction enzyme site Han EcoRI Yu XhoI.From commercially available purchase pCIneo-hTERT plasmid, it is dissolved in appropriate ultra-clean H2O or TE
In buffer, add 2uL10 × enzyme cutting buffering liquid and 18uL H2O, adds restricted enzyme EcoR I and each 0.5ul of Xho I,
37 DEG C of incubation 1h, 75 DEG C of heating 15min, inactivator, adding 5uL electrophoresis sample loading buffer (also can be by adding 0.5mol/L
EDTA) terminate reaction, routinely after PCR method amplification hTERT, collect amplified matter in case electrophoresis.(II) SV40LT and hTERT electricity
Swimming: 1. SV40LT (SV40DNA) electrophoresis: power taking swimming level agarose is made into 10% agarose gel with electrophoretic buffer, pours into
On the gel casting platform sealed, plug sample comb, after gelling is solid, from glue platform, removes envelope band, extracts comb, put into
In electrophoresis tank added with enough electrophoretic buffers, buffer exceeds gel surface about 1mm, by 10 appropriate × sample loading buffer system
Standby DNA sample, then adds sample in sample well with pipettor, and does suitable DNA molecular amount standard control thing simultaneously, connect
Energising pole, makes the DNA Ghandler motion that faces south move, and under the voltage of 1-10V/cm gel, electrophoresis is to when being sufficiently separated the distance of DNA fragmentation, closes
Close power supply.2. hTERT electrophoresis: power taking swimming level agarose is made into 10% agarose gel with electrophoretic buffer, pours into and has sealed
On gel casting platform, plug sample comb, after gelling is solid, from glue platform, removes envelope band, extracts comb, put into added with foot
In the electrophoresis tank of enough electrophoretic buffers, buffer exceeds gel surface about 1mm, prepares with 10 appropriate × sample loading buffer
HTERT enzyme action sample, then adds sample in sample well with pipettor, and does suitable standard control thing simultaneously, connects electricity
Pole, make hTERT face south Ghandler motion move, under the voltage of 1-10V/cm (80V) gel, electrophoresis is to the distance being sufficiently separated hTERT fragment
Time (30min), close power supply.(III) SV40LT and hTERT purification and recovery: 1. SV40LT purification and recovery: from agarose
Isolate about 2600bp SV40 large T antigen DNA: under 300-360nm long wave ultraviolet light source (use long wave ultraviolet light source in case
Only DNA damage) gel-tape containing target DNA fragments is cut in loading bag filter, in bag filter, add 2ml running buffer
Liquid, is allowed to submergence gel, and empties steam bubble, and bag filter level is put into electrophoresis tank (length direction is parallel with electrophoresis), adds suitable
Amount buffer, by bag filter submergence (about 6-7mm), switches on power, and 150 volts of electricity are washed, and observes and treat that DNA all removes under uviol lamp
Gel, changes direction of an electric field and continues energising 1 minute, and from bag filter, sucking-off buffer is in 1-5ml Eppendorf pipe, adds
1.5 times of volume n-butyl alcohol, mixing extracting removes EB, on desk centrifuge 2 minutes the most at a high speed, sucks upper strata butanol solution, as
This repeats secondary, adds equal-volume phenol chloroform (2) and extract 2 times in the solution of lower floor DNA, and supernatant is transferred to another
1/10 times of volume 3M NaAc, 2 times of volume pre-cooling dehydrated alcohol of addition in Eppendorf pipe, in 20 DEG C overnight, 12000g, 4 DEG C
Under be centrifuged 10 minutes, obtain DNA precipitation, abandon supernatant, after adding 70% washing with alcohol 2 times, abandon dry ethanol, add 50 μ l TE and dissolve
DNA.Additionally, can also be used with low melting-point agarose gel method, DNA filter membrane inserted sheet method etc. target DNA fragment is separated from gel, pure
Dissolve.2. hTERT purification and recovery: separate hTERT band from agarose: target will be contained under long wave ultraviolet light source
The gel-tape of hTERT fragment cuts in loading bag filter, adds 2ml electrophoretic buffer, be allowed to submergence gel in bag filter,
And empty steam bubble, bag filter level is put into electrophoresis tank (length direction is parallel with electrophoresis), adds appropriate amount of buffer solution by bag filter
Submergence (about 6-7mm), switches on power, and 150 volts of electricity are washed, and observes and treats that hTERT all removes gel, change electric field side under uviol lamp
To continuing energising 1 minute, from bag filter, sucking-off buffer is in 1-5ml Eppendorf pipe, adds 1.5 times of positive fourths of volume
Alcohol, mixing extracting removes EB, on desk centrifuge 2 minutes the most at a high speed, sucks upper strata butanol solution, so repeats secondary, from
Adding equal-volume phenol chloroform (2) in the solution of lower floor hTERT to extract 2 times, supernatant proceeds to add in another Eppendorf pipe 1/
10 times of volume 3M NaAc, 2 times of volume pre-cooling dehydrated alcohol, in 20 DEG C overnight, 12000g, it is centrifuged 10 minutes at 4 DEG C, obtains hTERT
Precipitation, abandons supernatant, abandons dry ethanol after adding 70% washing with alcohol 2 times, adds 50 μ l TE and dissolves hTERT.Additionally, can also be used with low
Purpose hTERT fragment is separated from gel, is purified by melting agarose gel method, hTERT filter membrane inserted sheet method etc..
2, SV40LT/pcDNA3.1 recon is built
Take 9 μ l above-mentioned DNA composition (0.1-5 μ g), 10 μ l 2 × connection buffer, 1 μ l 10mmol/L ATP, T4 DNA
Ligase (20~500 sticky end unit) or e. coli dna ligase, the mixing of pcDNA3.1 empty carrier, 15 DEG C of incubations
24h, is built into SV40LT/pcDNA3.1 recon.
3, hTERT/pLXSNneo recon is built
Take the hTERT composition (0.1-5 μ g) of the 9 above-mentioned purification of μ l, 1 μ l 10mmol/L ATP, 10ul Ligation Mix
Or the mixing of e. coli dna ligase, 2ul pLXSNneo empty carrier, 15 DEG C of incubation 24h, build pLXSNneo-hTERT restructuring
Son.
4, purification, expand, identify SV40LT/pcDNA3.1 and hTERT/pLXSNneo recon
(I) SV40LT/pcDNA3.1 recon amplification, separate and identify: the 1. preparation of E. coli competent: its base
This method is ice-cold CaCl2Or multiple divalent cation etc. processes antibacterial, feeding them into competence is converted, and uses
CaCl2Preparing fresh or freezing competent escherichia coli cell, be usually used in preparation in quantity competence antibacterial, this law is applicable to greatly
Most coli strains, operating process is summarized as follows: one single bacterium colony of picking from 37 DEG C of fresh plate cultivating 16~20h
(such as bacillus coli DH 5 2), or the 16~20h overnight culture that 1ml is fresh, forward to one containing 100mlLB culture medium 1L or
In 500ml flask, cultivate about 2~3h (rotary shakers 200~300r/min) in 37 DEG C of violent shakings, survey every 20~30min
Amount OD600 value ≈ 0.4, aseptically transfers to one, in ice-cold 50ml polypropylene centrifuge tube, at ice by antibacterial
After upper placement 10~20min, in 4 DEG C with SorvallGS2 rotary head (or the rotary head matched with its centrifuge tube) with 4000r/min from
Heart 10min, to reclaim cell, culture fluid reciprocal, pipe is inverted 1min so that the trace culture fluid of final residual flows to end, with 10ml
Ice-cold 0.1mMCaCl2Resuspended every part of precipitation, is put on ice, (or its corresponding with SorvallGS3 rotary head in 4 DEG C
Rotary head) it is centrifuged 10min with 4000r/min, to reclaim cell, pour out culture fluid, pipe is inverted 1min so that the trace of final residual
Amount culture fluid flows to end, the 0.1M CaCl of every 50ml initial incubation thing 2ml ice pre-cooling2Resuspended every part is sunk calmly, at this point it is possible to fast
Cell is distributed into aliquot by speed, freezes in liquid nitrogen, and-70 DEG C of storages are standby, with the sterile pipette tip of cooling from every kind of competent cell
Suspension respectively takes 200 μ l and transfers in aseptic microcentrifugal tube, often pipe add DNA or coupled reaction mixture (volume≤10 μ l,
DNA≤50ng), rotate gently to mix content, ice is placed 30min, centrifuge tube is put into following of pre-heating to 40 DEG C
On test tube rack in ring water-bath, place 90s~2min, do not shake test tube, quickly pipe is transferred in ice bath, make cell cool down
1~2min, every centrifuge tube adds 800 μ lSOC culture medium, with water-bath, culture medium is warmed to 37 DEG C, then pipe is transferred to 37 DEG C
On shaking table, incubation 45min makes bacteria resuscitation, and antibiotic-resistance marker's gene of expression plasmid coding, and proper volume is (every
Individual 90mm flat board is up to 200 μ l) competent cell that converted transfers to containing 200mmol/LMgSO4 and the SOB of corresponding antibiotic
In culture medium, flat board is placed in room temperature and is absorbed to liquid, be inverted plate, in 37 DEG C of cultivations, after 12~16h, may occur in which bacterium colony.
2. recon screening, expand and extract: select single colony inoculation in LB aseptic for 5mL with sterile toothpick or disinfection inoculation pin
In culture medium or rich medium (such as super broth or TB super broth culture medium), after overnight incubation, it is then added to 500mL and contains
In the 2L flask of LB culture medium (containing suitable antibiotic), cultivate to saturation (OD then at 37 DEG C600≈ 4, for improving yield,
Surface area should be used relatively big and the flask of band deflection plate is to increase venting quality as far as possible, shaking speed should be greater than 400r/min), in 4
DEG C, 6000g is centrifuged 10min, by the 4mL resuspended precipitation of GTL solution, and transfers in the high speed centrifugation pipe of a volume >=20mL
(bacterial precipitation can preserve at-20 DEG C or-70 DEG C of indefinite duration), adds the GTE solution containing 25mg/mL lysozyme that 1mL newly joins,
Resuspended precipitation, places 10min in room temperature, adds 10mL and newly joins NaOH/SDS solution, and mixes until liquid becomes equal gently
One, limpid and thickness, places 10min on ice, adds 7.5mL acetic acid solution, is gently mixed with suction pipe until viscosity declines
And form big precipitation, and 10min is placed on ice, in 4 DEG C, 20 000g are centrifuged 10min, and supernatant is poured into gently
In clean centrifuge tube, if there being visible drift that the isopropanol of 0.6 times of volume by several layers of filtered through gauze, can be added, reverse
Mixing, room temperature places 5~10min, and in room temperature, 1 500g is centrifuged 10min, adds 2mL70% ethanol and washs precipitation gently, then
Of short duration the most centrifugal, suck ethanol, and be vacuum dried (precipitation can be 4 DEG C of long-term preservations).3. the qualification of recon: above-mentioned from sense
By the DNA (containing SV40T/pcDNA3.1) extracted in state escherichia coli, ibid method restricted enzyme BamH I carries out enzyme action,
10g/L agarose gel electrophoresis is identified, it is thus achieved that 2 bands of size about 2600bp and 5600bp, the former meets in GenBank
The size of SV40T fragment.(II) hTERT/pLXSNneo recon purification, expand, identify: the 1. system of E. coli competent
Standby: its basic skills is ice-cold CaCl2Or multiple divalent cation etc. processes antibacterial, feed them into competence and turned
Change, use CaCl2Preparing fresh or freezing competent escherichia coli cell, be usually used in preparation in quantity competence antibacterial, this law is fitted
For most of coli strains, operating process is summarized as follows: picking one from 37 DEG C of fresh plate cultivating 16~20h
Single bacterium colony (such as bacillus coli DH 5 2), or the 16~20h overnight culture that 1ml is fresh, forward one to containing 100mlLB culture medium
1L or 500ml flask in, cultivate about 2~3h (rotary shakers 200~300r/min) in 37 DEG C of violent shakings, every 20~
30min measures OD600 value ≈ 0.4, aseptically antibacterial is transferred to one, ice-cold 50ml polypropylene centrifuge tube
In, place 10~20min on ice, in 4 DEG C with Sorvall6S2 rotary head (or the rotary head matched with its centrifuge tube) with 4000r/
Min is centrifuged 10min, to reclaim cell, and culture fluid reciprocal, pipe is inverted 1min so that the trace culture fluid of final residual flows to end,
With the ice-cold 0.1mMCaCl of 10ml2Resuspended every part of precipitation, is put on ice, in 4 DEG C with SorvallGS3 rotary head (or and its
Corresponding rotary head) it is centrifuged 10min with 4000r/min, to reclaim cell, pour out culture fluid, pipe is inverted 1min so that the most residual
The trace culture fluid stayed flows to end, the 0.1M CaCl of every 50ml initial incubation thing 2ml ice pre-cooling2Resuspended every part is sunk calmly, rapidly will
Cell is distributed into aliquot, freezes in liquid nitrogen, and-70 DEG C of storages are standby.2. with competence escherichia coli purification and amplification hTERT/
PLXSNneo recon: take 200 μ l from every kind of competent cell suspension respectively with the sterile pipette tip of cooling and transfer to aseptic
In microcentrifugal tube, often pipe adds DNA or coupled reaction mixture (volume≤10 μ l, DNA≤50ng), rotate gently with mixed
Even content, places 30min in ice, centrifuge tube is put into pre-heating to the test tube rack in the circulator bath of 40 DEG C, places
90s~2min, does not shake test tube, quickly transfers in ice bath by pipe, makes cell cooling 1~2min, and every centrifuge tube adds 800 μ
LSOC culture medium, is warmed to 37 DEG C with water-bath by culture medium, is then transferred to by pipe on 37 DEG C of shaking tables, and incubation 45min makes antibacterial
Recovery, and antibiotic-resistance marker's gene of expression plasmid coding, turn by proper volume (every 90mm flat board is up to 200 μ l)
The competent cell changed is transferred to, in the SOB culture medium containing 200mmol/LMgS04 and corresponding antibiotic, flat board is placed in room temperature
Absorbed to liquid, be inverted plate, in 37 DEG C of cultivations, after 12~16h, may occur in which bacterium colony.3. screen, expand recon: with aseptic
Toothpick or disinfection inoculation pin select single colony inoculation in LB culture medium aseptic for 5mL or rich medium (such as super broth or
TB super broth culture medium) in, after overnight incubation, it is then added to the 500mL 2L containing LB culture medium (containing suitable antibiotic) and burns
In Ping, cultivate to saturation (OD then at 37 DEG C600≈ 4, for improving yield, should use surface area relatively big and the burning of band deflection plate
Bottle is to increase venting quality as far as possible, and shaking speed should be greater than 400r/min), in 4 DEG C, 6000g is centrifuged 10min, with 4mL GTL solution
Resuspended precipitation, and transfer in the high speed centrifugation pipe of a volume >=20mL that (bacterial precipitation can be unlimited at-20 DEG C or-70 DEG C
Phase preserves), add the GTE solution containing 25mg/mL lysozyme that 1mL newly joins, resuspended precipitation, place 10min in room temperature, add
10mL newly joins NaOH/SDS solution, and mixing, until liquid becomes homogeneous, limpid and thickness, places 10min on ice gently,
Add 7.5mL acetic acid solution, be gently mixed with suction pipe until viscosity declines and formed big precipitation, place 10min on ice,
In 4 DEG C, 20 000g are centrifuged 10min, are poured into gently by supernatant in another clean centrifuge tube, if there being visible floating
Thing by several layers of filtered through gauze, can add the isopropanol of 0.6 times of volume, reverse mixing, and room temperature places 5~10min, in room temperature, 1
500g is centrifuged 10min, adds 2mL70% ethanol and washs precipitation gently, the ofest short duration the most centrifugal, sucks ethanol, and vacuum is done
Dry (precipitation can be 4 DEG C of long-term preservations).4. the qualification of recombiant plasmid and amplification: the single bacterium colony on picking plate, is inoculated in 3ml and contains
In 100ug/ml ampicillin LB culture medium, 37 DEG C, 250r/min shaking table is cultivated, collection culture after 14h, 4 DEG C,
10000r/min is centrifuged 5min, extracts in a small amount and purification of Recombinant plasmid by test kit description;With the double enzyme of EcoRI and HindIII
Cut recombiant plasmid reaction system: each 0.5ul of restricted enzyme, 10 × buffer 2ul, recombiant plasmid 10ul, adding water complements to
20ul, 37 DEG C of enzyme action 1h.Digestion products carries out 0.8% sepharose electrophoresis, time 30min, gel imaging under 80V voltage conditions
System is taken pictures;Measure the sequence of recombiant plasmid routinely;Recombiant plasmid, will be containing this plasmid after enzyme action, order-checking are identified accurately
Microbionation in LB culture fluid, amplification cultivation, carry out heavy dose of plasmid by heavy dose of plasmid extraction test kit description and take out
Purification, ultraviolet spectrophotometer is standby after measuring plasmid concentration and purity.
(3) macrophage strain is built
1, co-transfection SV40LT and hTERT causes macrophage immortalization
Recon SV40LT/pcDNA3.1 and hTERT/pLXSNneo is imported macrophage, builds macrophage strain, and
Row amplification culture, method particularly includes: in 1.5ml microcentrifugal tube, prepare following solutions: take A pipe, by SV40LT/pcDNA3.1
It is dissolved in 50 μ l serum-free mediums;Take B pipe, hTERT/pLXSNneo is dissolved in 50 μ l serum-free mediums;Then C is taken
20 μ l liposome Lipofectamine are dissolved in 80 μ l serum-free mediums by pipe, by A pipe, B pipe and the mixing of C pipe, in room
45min is stood under conditions of temperature.Above-mentioned T lymphocyte is washed 2 times with serum-free medium.Exist the most respectively
In Lipofectamine-SV40LT/pcDNA3.1 and Lipofectamine-hTERT/pLXSNneo mixture add 1ml without
Serum free culture system liquid, mixes gently, then drops to, in above-mentioned T lymphocyte, be subsequently adding 1ml serum-free medium (hyclone
Concentration is 20ml/L), at CO2Incubator cultivates 10h, and sucking-off transfection liquid, (hyclone concentration is to add 4ml complete culture solution
20%), continuing to cultivate 20h, discard culture fluid, changing concentration is 400mg L-1G418 culture fluid continue cultivate, after 8 days select
Select after living cells makees amplification culture, then strengthen G418 concentration to 800mg L-1, raw by stablizing in the G418 environment of high concentration
Long cell proceeds amplification cultivation.Cultivate about 9 days Microscopic observations, it is seen that macrophage significantly increases, occur assembling now
As.If cell increases slow, or cell density is low, or medium pH value is acidity, and culture fluid is partly measured in sucking-off, carries out equivalent and changes
Liquid.Transfer in 75ml culture bottle when total amount reaches 14ml, every 2-3 week adds 5-10ml fresh culture.Cell is cultivated extremely
15-20 week (the about the 135th generation), still in exponential phase, i.e. cell is accelerated and incubation time is multiplication relation, dead
Cell (judges the increase situation of cell quantity less than 10% by reading the scale of culture vessel;Reflected by trypan blue staining
Other dead cell and living cells.Because normal living cells, after birth structural integrity, it is possible to repel, make trypan blue can not enter born of the same parents
In;And the cell of loss of activity, the permeability of after birth increases, and can be dyed blueness by trypan blue, can determine whether as cell the most dead.
Method is to draw weekly a certain amount of suspension culture, mixes rearmounted room temperature 5~10 minutes with Trypan Blue agent, then makes
Become cell sheet, under the microscope 1000 total cellular score of counting, calculate the dead cell and the hundred of non-staining living cells of coloring
Proportion by subtraction).Hereafter along with increase and the prolongation of incubation time of cultivation algebraically, the increase of cell quantity is slack-off, dead cell more comes
The most, until cell is not further added by, even dissolve, reduce, all dead.When total amount reaches 45ml, put in 50ml centrifuge tube,
Centrifugal 1500 turns, 10 minutes, abandon supernatant, add 3ml freezing media (5% DMSO (dimethyl sufoxide),
95%FBS) mixing, (cell concentration is about 10 to become cell suspending liquid5/ml).Cryopreservation tube subpackage, 1ml/ manages, puts-20 DEG C of 2h, then
Put-70 DEG C of 2h, the most frozen in-196 DEG C of liquid nitrogen (or under zero setting immediately 80 degree, move in liquid nitrogen container after 1-2 hour).With this
Build immortalization macrophage strain (being).
2, the biological characteristics of macrophage strain is identified
1. form under observation of cell mirror: visible macrophage slurry is abundant, irregularly, flexible under liquid;2. observe thin
Intracellular growth curve: take the preferable transfectional cell of growth, make cell suspension, through counting, take 1.4 × 10 respectively4Cell is inoculated in
30 contain 15 FBS low sugar DMEM culture medium culturing bottles, take 2 bottles of cells every day and count, calculate average, Continuous Observation until
Cell quantity is decreased obviously, and the cell giving no count every 2 days after cultivating 3 days changes liquid, uses same method to observe transfectional cell
Growing state in hepato ZYME-SFM serum-free medium, result is with incubation time as transverse axis, and cell quantity is the longitudinal axis
(logarithm), be depicted on semi-logarithmic scale make after curve the growth curve of this cell, immortalized cell line is in typically
" S " feature or " arched roof " are formed;3. chromosome is checked: by analyzing karyotype, if karyotype is diploid
" 46, XX " or " 46, XY ", or identical with the caryogram of primary cell, then illustrate that this cell line does not occur the vicious transformation (simultaneously can
With whether flow cytometry analysis cell line occurs abnormal DNA colony, if it did not, tumor does not occurs in explanation cell line yet
Feature);4. nude mice tumorigenesis test: by the cell of hTERT and SV40LT immortalization with 3 × 107Inoculation nude mice dorsal sc, 2
After Yue, 4 nude mices are showed no tumor and are formed, it was demonstrated that this cell is non-malign cells;5. hTERT and SV40 in transfectional cell DNA
Big T gene test: as with Immunohistochemical detection, dye in the nucleus of hTERT and SV40 transfection visible a large amount of browns
Grain, shows that hTERT or SV40LT antigen has been integrated into intracellular;Also the expression in cell of the T antigen can be detected by RT-PCR method,
The wherein primer of T antigen: forward primer (A4239) 5 '-GTT ATG ATT ATA ACT GTT ATG-3 ', downstream primer
(S4496)5’-GAA ATG CCA TCT AGT GAT-3’;The a length of 268bp of amplified production, amplification condition is 94 DEG C, 5min,
I.e.: (94 DEG C, 1min;55 DEG C, 1min ,-0.5 DEG C/circulation;72 DEG C, 1min) × 30, (94 DEG C, 30S;40 DEG C, 30S, 72 DEG C,
30S) × 15, amplification system is 50 μ l:[Mg2+] 2mmol/L, dNTPs200 μm ol/L, primer concentration 0.4 μm ol/L, Taq 1U,
Template 5 μ l;Experimental group (carries out cDNA with reference to commercially available cDNA the first chain synthetic agent box with the cDNA of the 19th generation cell as template
One chain synthesis, product-20 DEG C preservation);Negative control sets two, does template with the cDNA of sterilized water, primary cell respectively, positive
Comparison (is extracted SV40 DNA with reference to SDS-proteinase-K pathway with SV40 DNA as template, because SV40 virus is without peplos, is not used
SDS rupture of membranes, takes 5 μ l and carries out 1.5% agarose gel electrophoresis detection, and remaining-20 DEG C save backup);6. mrna expression product is surveyed
Fixed: T antigen mRNA RT-PCR product checks order: takes the amplified production of 100 μ l systems, reclaims test kit (Takara, day with gel
This) reclaim product, take 2 μ l DNA solutions and dilute 100 times, survey concentration, remaining DNA and each 10 μ l of upstream and downstream primer surveys
Sequence.7. Flow cytometry: the cell proportion synthesizing, dividing in detection the 19th continuous cell line, if its multiplication capacity is obvious
Strengthening than not building the normal cell being, explanation is the result that hTERT and SV40 large T antigen is integrated, expressed.8. determined dna sequence:
Sequenator detection routinely, shows hTERT and SV40 large T antigen gene order.In a word, the spy that the strain of immortalization macrophage has
Property be: 1. macrophage transfection SV40LT and hTERT gene thus can cultivate by Long Term Passages;2. the chromosome core of macrophage
Type is diploid, i.e. " 46, XX " or " 46, XY ";3. the growth curve of macrophage is such as with incubation time as transverse axis, cell quantity
For the longitudinal axis, in " S " feature or " arched roof " is formed in hepato ZYME-SFM serum-free medium;4. cell can not be at soft fine jade
Growth in fat (forms clone);5. cell is non-malign cells, nude mice tumorigenesis negative;6. the DNA of cell integrates simultaneously
SV40LT and hTERT gene, expresses the mRNA product of SV40LT and hTERT gene;7. in-vitro cultivation 15-20 week is (about
135th generation) still in exponential phase;8. can the most frozen, Long Term Passages cultivation.
3, the function of macrophage strain is detected
Macrophage strain being inoculated in 96 well culture plates, observation of cell growing state, after 7-10 days, cell clone grows
When area reaches 1/10 cell hole, go culture supernatant, the culture hole that growth selection is in good condition, labelling cell strain under microscope
The position of growth, size, use aseptic rifle head to draw cell clone to the new cultivation having complete medium in the position of mark
In hole, doubling dilution counts hole to below the most successively, 37 DEG C, cultivates about one week, basis of microscopic observation in 5%CO2 incubator
Cell growth status, when cell clone covers with to hole floor space more than 1/10, takes cell or culture supernatant detection macrophage
The function of strain.Including: 1. macrophage strain phagocytosis antibacterial Function detection: macrophage is hanged with staphylococcus or Candida albicans
Liquid mixing incubation, smear, fixing, serge blue liquid dyes, and in oil Microscopic observation phagocytosis situation, counts phagocytosis antibacterial and does not gulps down
Bite the macrophage number ratio of antibacterial, to swallow antibacterial function strong macrophage alternately positive clone strain.The hugest bite thin
Born of the same parents' strain phagocytosis HIV Function detection: the blood plasma taking acquired immune deficiency syndrome (AIDS) (AIDS) patient that Disease Control and Prevention Center preserves mixes training with macrophage strain
After Yanging, separate cell strain, PBS 3 times, measure the phagocyte strain through cracking and swallow the function of HIV, with specific reference to HIV-
1p24 antigen detection kit (euzymelinked immunosorbent assay (ELISA), inspiration bio tech ltd, Shanghai) operate, with concentration known 0pg/ml,
The p24 antigen of 0.5pg/ml, 1pg/ml, 2.5pg/ml, 5pg/ml, 20pg/ml, 40pg/ml, 80pg/ml is as comparison, minimum
Detection limit is less than 5pg/ml, measurement range 0~400pg/ml, range of linearity 0.5pg/ml~80pg/ml, and in 15min, 450nm surveys
Determining absorbance (OD), blank calibration object absorbance is not higher than 0.050, and 0pg absorbance is not higher than 0.100,1000pg/
Ml absorbance is not less than 1.000, is considered as positive as absorbance > 0.12.Concrete test kit description of pressing operates.The hugest
Phagocyte strain produce macrophage cytokines detection: with MIF (MIF) ELISA detection kit (on
Hai Bairui bio tech ltd) by specification operation, detection range is 0~800pg/ml, and sensitivity is 1.0pg/ml, can
Under white background, directly detecting by an unaided eye: in reacting hole, color is the deepest, the positive is the strongest, and negative reaction is colourless or the most shallow, depends on
According to the depth in color, with "+", "-" number represents.Also OD value can be surveyed: on ELISA detector, in 450nm (if with ABTS
Colour developing, then 410nm) place, survey each hole OD value after returning to zero with blank control wells, if 2.1 times of the negative control OD value more than regulation,
It is the positive, specifically presses the operation of test kit description.MIF integrates cytokine, somatomedin, hormone and enzyme characteristic
Multi-effect protein molecular, plays the effect of central as the regulatory factor of inherent immunity and inflammatory reaction, in various infection and
Active chronic inflammation disease plays panimmunity function.According to testing result, select the culture hole with stronger phagocytic function
In cell clone repeat next round dilution cultivate, repeat 2-3 wheel, detection function-stable after take out, proceed to culture bottle expand
Increase and cultivate.
4, the frozen and recovery of macrophage strain
Preserve first 12 hours and adjust cell growth state, take one bottle of growth vigorous, after the cell that form is good, suitably digestion
Making cell suspension, 1000r/min is centrifuged 5min, removes supernatant, flicks and makes cell loose at the bottom of pipe, adds 4 DEG C of 9 parts preserved complete
Full culture fluid and 1 part of DMSO, subpackage cell cryopreservation tube, 1mL/ manages, and cryopreservation tube is put into liquid nitrogen after taking-up by-70 DEG C of refrigerator overnight
Container saves backup.Get out the hot water of about 40 DEG C before recovery, cryopreservation tube is carefully taken out from liquid nitrogen, be immediately placed in heat
In water, uniformly shake makes cell thawing, is centrifuged 5min at 1000r/min, opens and freeze in superclean bench under aseptic condition after defrosting
Depositing pipe, the cell complete culture solution after thawing washed once, and is then centrifuged 5min at 1000r/min, supernatant discarded, in case
Make amplification cultivation.
5, the amplification of macrophage strain
Moving in culture bottle after using complete culture solution the most resuspended above-mentioned cell precipitation, put 37 DEG C, 5%CO2 cultivates
Case is cultivated.Repeatedly pass on amplification cultivation, until required macrophage strain quantity, every Secondary Culture 10 generation, detect huge biting carefully
The function of born of the same parents' strain, sees whether stable.Continue in several bottles, carry out large-scale culture, save backup.
The technical scheme of the application, the primary cell used includes being directly separated and huge the biting carefully in stem cell induction source
Born of the same parents, dendritic cell, neurogliocyte, CD4+T cell, mononuclear cell and by chemical coupling, crosslinking, affine absorption system
The granule being coated with CD4 molecule become, and/or the granule similar to CD4+ cell function.The construction method of immortalized cell line
Hybridoma technology is fused including conventional cell.Plasmid vector includes selecting SV40LT/pLXSN, hTERT/pLPCX, SV40LT/
PcDNA3.1 (-) and hTERT/pLXSNneo.The composition causing immortalization includes reverse transcription virus gene, SV40LT, hTERT, EB
Virus, oncogene, cell growth stimulant and derivant and include CD 3-resisting monoclonal antibody, AntiCD3 McAb/CD28 double antibody
At interior CD4+ cell surface antibodies.
Two, the preparation of depurator
1, the filling of cleanser
The macrophage strain present invention prepared, after cleaning with physiological saline solution, then is centrifuged 5min with 1000r/min
(low speed is centrifuged in short-term), takes cell precipitation assembling acrylate etc high-biocompatibility material (with plasma separator material phase
With) the cylindrical cleaning device made, to 4/5, then add cells frozen storing liquid (containing 30% hyclone, 12% dimethyl sulfoxide
RPMI-1640), make cell concentration reach 80%, shake up gently, sealing, through 4 DEG C, 0.5h;-20 DEG C, 2h;-70 DEG C, overnight, enter-
196 DEG C of liquid nitrogen cryopreservations are standby.When defrosting uses, need be put in the 37 DEG C of water-baths having been warmed up by cryopreservation tube rapidly, and constantly
Shake, makes the liquid in pipe melt rapidly, uses after then cleaning with physiological saline solution.When preparing cleanser, preserve thin
The medium of born of the same parents includes selecting normal saline, regular growth culture fluid, cells frozen storing liquid.Macrophage strain preparation with phagocytosis HIV
During cleanser, its concentration is 80%, and when preparing cleanser with the immunocyte and immune particle adsorbing HIV, its concentration is 95%
Above.Various kinds of cell can be hybridly prepared into cleanser.
2, the specification of depurator
Depurator can be the cylinder that footpath, the end is little, footpath, top is big, or square, infundibulate, and volume is 200~300ml, imports and exports
Being equipped with cell screen cloth, footpath, import department top sieve number is 800 mesh;Footpath sieve number at the bottom of exit be 2.0~5.0 mesh (2.5~
5.0 mesh are equivalent to 0.1~0.2 micron or 100~200 nanometers), specifically can be made into 2.0 mesh, 2.5 mesh, 3.0 mesh, 3.5 mesh, 4.0
7 kinds of different sizes of mesh, 4.5 mesh and 5.0 mesh, in order to stop the antibacterial of the inhibition of HIV or bigger of 120 nanometers;Liquid outlet
The cell strainer that mesh number is 100 mesh (being equivalent to 4 microns) is set, in order to stop the cell that may leach;Liquid entrance and net
Relief area, the beneficially stability of system circulation it is provided with between sieve.
3, the material of depurator
Blood purification selects the macromolecular material of acrylate etc, it is desirable to good biocompatibility, activates benefit hardly
Body, do not cause inflammatory reaction, do not cause the change of leukocyte, platelet, blood oxygen pressure, complement C 3, C5a.Can pass through covalency,
The methods such as grafting, polymerization improve the structure of material, the regulation inhomogeneities on surface, hydrophilic, minimizing to blood coagulation and oxidative stress
Impact thus improve biocompatibility, reduce complication generation.Hydrophilic gel is added, by 2 methyl-prop at adsorber inner surface
Alkene acyloxyethyl phosphocholine-butyl methacrylate is solidificated in cellulose acetate membrane, by controlling wet-spinning procedure, can generate
CA/PMB30, CA/PMB80 and CA/PMB30-80, have higher blood and cell compatibility.Some had anticoagulation
Material be solidificated on the material of carrier or adsorber inner surface, can suppress blood coagulation, improve biocompatibility, also can reduce
Heparin consumption, and likely realize no-rod tractor.It is attached to heparin covalent polyether sulfone surface, both maintain the mechanics of polyether sulfone
Performance, can improve again the anticoagulation function of adsorber inner surface.Covalent immobilisation linoleic acid film on cellulose acetate film, or by covalency
It is attached to polyacrylic linoleic acid and is grafted onto polysulfone membrane surface, can have more preferable histocompatibility and anticoagulant effect.
Along with macromolecular material and the development of nanotechnology, the material close with Human vascular endothelial will go out in the near future
Existing.
Three, the preparation of separator
(1) preparation of blood separator
1, preparation principle: 1. hemocyte, antibacterial, the molecular size of virus: in blood of human body, visible component (cell) is big
Little it is: normocyte is about 7 microns (μm), is the discoid cell of concave-concave;Leukocyte is divided into 5 kinds, and neutrophilic granulocyte is about
12 μm, eosinophilic granulocyte is more bigger, and basophilic granulocyte is close with neutrophilic granulocyte, and small lymphocyte 6-8 μm, with erythrocyte
Approximation, mononuclear cell is maximum, about 15-20 μm.Platelet is disc, diameter 1~4 microns to 7~8 microns, the blood of people
Platelet average diameter is 2-4 micron, thick 0.5~1.5 micron.The size of antibacterial is: the diameter of coccus about 0.75-1.25 μm it
Between, bacillus length is about in 2-5 μm, and spirillum is about 100-200 μm.Virus size with nanometer (nm) as unit [1cm=
10mm, 1mm=1000 μm, 1 μm=1000nm], between different virus, difference in size is very big, minimum such as the gemnivirus of plant
(Geminiviruses) diameter only 18-20nm, maximum animal poxvirus (Poxviruses) size reach 300-450nm ×
170-260nm, the longest as filamentous virus section (Filoviridae) virion size be 80nm × 790-14000nm, most
The diameter of single virus particle is at about 100nm, and HIV (human immunodeficiency virus) is 100-120nm (0.1-0.12 μm).2. HIV sufferers blood
Related compounds present in liquid: (gp120 with the CD4+ Cell binding of HIV cell surface is substantially for multinucleated giant cell
Long-pending HIV cell), gp120 cell (surface is with the presence of gp120 but with the HIV cell of individual cells), gene integration
Cell (integrate and have HIV double-stranded DNA, but the HIV that cell surface does not has gp120 is thin by HIV (human immunodeficiency virus) infection initial stage or incubation period
Born of the same parents), normal white cell (being uninfected by granulocyte that the individual cells of HIV exists, mononuclear cell, lymphocyte), erythrocyte, blood little
Plate, chemical analysis (protein, saccharide, lipid, electrolyte etc.), free HIV, antibacterial and other microorganisms.3. multinuclear is big and small
Born of the same parents are natural large volume cell;Gp120 cell and gene integration cell can make cell by the immunoreation of antigen and antibody
Coagulation is large volume many cells polymer;Free HIV can be changed into large volume composition by carrier granular/immunoreation.④
According to above-mentioned 3 points, can prepare can by individual cells but large volume cell or the blood separator of granule can not be passed through.5. select
The material of the selective adsorption function of apparatus, screens out the HIV cell in blood through the extracorporeal circulation of blood branch road of the present invention.
2, the material of blood separator and requirement: with the depurator of the present invention, selects poly-vinegar non-woven fabrics, acetate fiber, de-
Fat is cotton, it is desirable to good biocompatibility, hardly activating complement, do not cause inflammatory reaction and leukocyte, platelet, blood oxygen to divide
Pressure, the change of C3a, C5a.
3, the model of blood separator: the profile of blood separator is prepared as column construction (with acetate fiber or absorbent cotton
For material make filter element), flat structure (making filter element for material with poly-vinegar non-woven fabrics);Aperture be prepared as 150~250 μm, 50
~150 μm, 15~40 μm, 8~15 μm, 5~8 μm, 3~5 μm, 1~2 models of μm.
4, the application of principle of blood separator: select the separator of different model, principle according to the state of an illness of HIV sufferers
Upper first selection large aperture model does pre-sieving, the then model in selection of small aperture.Severe HIV sufferers often occurs serious
Opportunistic infection, containing different size of composition in blood.As the fungus containing especially big volume, spirillum, tumor cell and
His foreign body, then selecting aperture is 150~250 μm or the separator of 50~150 μm;As bitten carefully for the monokaryon of sieving HIV is huge
Born of the same parents, multinucleated giant cell, many cells polymer and be adsorbed with the particulate matter of HIV, and in order to replace easily by HIV
CD4+ cell, then select 15~40 μm, 8~15 μm, 5~8 μm, 3~5 models of μm etc.These several models approximate or are less than
The volume of single erythrocyte, neutrophilic granulocyte, small lymphocyte in blood, but erythrocyte, neutrophilic granulocyte and macrophage tool
There is the characteristic of amoeboid movement, can be by the micropore less than own vol.
(2) preparation of plasma separator
(1) preparation principle: prepare according to the molecular size of hemocyte and blood plasma components.Such as visible component in blood of human body
The size of (hemocyte) is: normocyte is about 7 microns (μm), is the discoid cell of concave-concave;Leukocyte is divided into 5 kinds,
Neutrophilic granulocyte about 12 μm, eosinophilic granulocyte is more bigger, and basophilic granulocyte is close with neutrophilic granulocyte, small lymphocyte 6-
8 μm, approximate with erythrocyte, and mononuclear cell is maximum, about 15-20 μm.Platelet is disc, diameter 1~4 microns to 7~8 microns
, the platelet mean diameter of people is 2-4 micron, thick 0.5~1.5 micron.
(2) material: can be selected for poly-vinegar non-woven fabrics, acetate fiber, absorbent cotton etc., it is desirable to good biocompatibility, swash hardly
Live complement, do not cause inflammatory reaction, do not cause the change of leukocyte, platelet, blood oxygen pressure, complement C 3, C5a.Can be by altogether
Valency, be grafted, the method such as polymerization improves the structure of material, the regulation microinhomogeneities on surface, hydrophilic, minimizing be to blood coagulation and oxygen
Change stress impact thus improve sieving adequacy and biocompatibility, the generation of minimizing complication.
(3) type and spec: for the profile of separator, can prepare as filter element with the material such as acetate fiber or absorbent cotton
Become column construction, be prepared as the shapes such as flat structure with materials such as poly-vinegar non-woven fabrics as filter element;By hemocyte to be separated and blood
The molecular size of slurry composition determines aperture.Plasma separator stable in properties involved in the present invention, good biocompatibility, penetrating
Hollow fibre type filter made by the high molecular polymer that property is high, hollow-fiber film a diameter of 270~370 μm, and film thickness is 50 μm,
Aperture is 0.2~0.6 μm, and fibre length is 13.5~26 μm.This hole is only permitted blood plasma and is filtered, but can stop that all of cell becomes
Point.
Four, the component of acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument
1, key member: (1) blood separator: screen out with multinucleated giant cell or many cells polymer for by volume size
The HIV cell that state exists, is i.e. used for removing endoglobar HIV;(2) plasma separator: be used for separating single blood thin
Born of the same parents and blood plasma;(3) plasma purification device: the HIV in adsorbed plasma.
2, additional member: include blood pump, heparin pump, sound pulse pressure and air monitering, temperature control system, off gas system,
The part compositions such as monitored conductivity system, ultrafiltration monitoring and leakage blood monitoring.(1) blood pump (Blood Pump): be used for promoting blood
Circulating to maintain being smoothed out of blood purification treatment, usual blood pump part often has rotary test speed function, to monitor patient
Blood circumstance, therefore blood pump runner and flute pitch set and want accurately and it needs to often adjust, according to the feelings of bloody path pump line
Condition, is typically set as 3.2~3.3mm by spacing, can not be the most loose, and blood flow detection otherwise can be caused to be forbidden;Also can not be too tight, otherwise
Pipe breakage can be caused.(2) heparin pump (Heparin Pump): heparin pump is equivalent to the micro-injection pump applied clinically, uses
To continue injecting heparin in sieving pipeline (patient blood), owing to the blood of patient circulates and air contact, easily in vitro
There is blood coagulation phenomenon, use heparin pump to be possible to prevent the generation of blood coagulation.(3) sound pulse pressure monitoring: arterial blood pressure monitoring mainly in order to
The stopping state of dynamic monitoring blood separator micropore, additionally in order to monitor the change of extracorporeal circulation thrombosis, solidification and pressure.When
During blood flow deficiency, arterial pressure will reduce;When having blood coagulation, thrombosis, particularly during separator blockage of the micro orifice, arterial pressure will
Raise;Venous pressure monitoring is used for monitoring the pressure of pipeline blood backflow, when separator blockage of the micro orifice, blood coagulation, thrombosis, blood flow
When deficiency and venous return syringe needle come off, venous pressure will decline, if the distortion blocking of bloody path return duct or backflow syringe needle
When there is blocking, venous pressure will raise.(4) air monitering (Air Detector): be used for monitoring the air gas of blood pathway
Bubble, the principle of general ultrasonic listening, in order to avoid patient occurs air embolism to arrange.When having monitored air bubble
Time, detecting system can drive artery and vein bloody path folder to carry out blocking blood flow, prevent the generation of danger.
In a word, on the basis of key member of the present invention and additional member, Import computer regulates and controls and makes the people of operation
Property, the personalization for the treatment of, the safety of design, and modularity, automatically monitoring and regulation and control, liquid crystal display, judge voluntarily to warn
The blood purifying therapeutical instrument that the report micro computer such as reason and ring off signal processes.
Five, the connecting path of acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument and using method
1, install: such as Fig. 1, with sterile working's connecting components, including blood separator, plasma separator, plasma purification
Device and each circulation line.
2, aerofluxus: with physiological saline solution topping up separator, depurator and each circulation line, gets rid of separator, depurator
And gas in circulation line, bubble, go through, confirm without use after gas, bubble.
3, logical liquid: arterial blood line pipe (1) is connected the arteries of HIV sufferers, the row of going through the most again
Gas is the most complete, and liquid stream is the most unobstructed, and avoids managing the pollution of interior flow liquid.
4, anticoagulant: inject anticoagulant (heparin) from heparin pump (2) to liquid stream, be 2500 ∪ or 20~30 ∪/kg for the first time.
5, start: one end of arterial blood line pipe (1) is connected with arteries, venous line (15) is connected venous blood
Pipe, then opens blood pump (2), and blood flow is 100~150ml/min, such as Fig. 1, when arterial blood through arterial blood line pipe (1),
When heparin and blood pump (2) enter blood separator (3), the large volume multinucleated giant cell formed because of HIV is delayed at
In blood separator (3), mononuclear blood cell and blood plasma export (4), blood pump (6) and circulation line (7) through blood successively and flow into
Plasma separator (8), the blood plasma of separation flows into now open depurator (11) through blood plasma pump (9) and blood vessel (10) successively,
Blood plasma to be full of, about 10 minutes, begin paying out blood plasma, through export pipeline (13) flow out, synchronize to depurator (12) irrigate blood plasma,
When blood plasma in depurator (11) has nearly flowed, starting again at perfusion blood plasma, now depurator (12) begins paying out blood plasma, and two
The depurator (11) of individual parallel connection and (12) are alternately.As represented Fig. 2 institute of the internal structure of the blood separator (3) in Fig. 1
Show, the tube wall of the inner chamber (2) of blood separator (1) has a lot of micropore (3), multinucleated giant cell (4) micropore (3) can not be filtered and
Be delayed at inner chamber (2), thus can be eliminated, can by micropore (3), the mononuclear blood cell (5) of small size and blood plasma enters
Enter exocoel (6), then flow out through outlet (7), and then isolate hemocyte and blood plasma through the plasma separator (8) shown in Fig. 1.As
Shown in Fig. 3 of the internal structure of the plasma separator (8) in expression Fig. 1, the tube wall of the inner chamber (2) of plasma separator (1) has
A lot of micropores (3), it is impossible to export (8) by the mononuclear blood cell (4) of micropore (3) through the hemocyte with switchable valve and flow
Go out, enter the hemocyte export pipeline (14) shown in Fig. 1;Blood plasma can be entered by the blood plasma of micropore (3) and chemical composition (5) thereof
Separator exocoel (6), then enters depurator through the blood plasma pump (9) shown in blood plasma flow export (7), Fig. 1 and blood vessel (10).As
Represent in Fig. 1 shown in Fig. 4 of depurator (11) and (12) internal structure, when the blood plasma containing HIV (3) enters depurator (1),
The macrophage phagocytic body (4) no longer moved down is formed, by clearly after macrophage (2) phagocytosis that HIV therein (3) is cleaned in device
Except purifying individual cells that blood plasma separates through the export pipeline (13) shown in Fig. 1 with plasma separator (8) at outlet after HIV
Conflux through venous line (15) after converging in road (14) place.So remove HIV, purify blood, until the plasma circulation being previously set
Amount (usually 9L), treatment just ends, and whole therapeutic process is by computer control, and can detect duty at any time, makes
By convenient, automatization and safety.
Six, the checking of acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument effect
1, blood separator filters the checking of HIV cell effect
HIV-p24 testing result (p24:pg/ml) in the large, medium and small leukocyte of table 1 AIDS patient peripheral blood
The present inventor, according to the basic skills of the present invention, has done following simple confirmatory experiment: take Disease Control and Prevention Center and infection
The some parts of anticoagulated whole blood of acquired immune deficiency syndrome (AIDS) (AIDS) patient made a definite diagnosis that sick laboratory biological Sample Storehouse preserves, respectively peek part phase
It is mixed into 5 examples with the anticoagulated whole blood of abo blood group, makes blood flow volume sufficiently large, then entrust blood station, center to press the blood of composition blood transfusion
Liquid becomes component separation, isolates leukocyte, erythrocyte, blood plasma through blood component piece-rate system, takes leukocyte composition routinely
Centrifugation, inhales and abandons supernatant, and with appropriate normal saline suspension leukocyte cell pellet, the gp120 being subsequently adding proper ratio resists
Body (Guang Rui bio tech ltd, Shanghai), mixes rearmounted 37 DEG C and reacts 5 minutes, then with blood that aperture is 20~30um
Composition piece-rate system isolates the leukocyte (the biggest leukocyte) of large volume, to the leukocyte filtrate filtered further with hole
Footpath be 15~25um blood component piece-rate system isolate the leukocyte (referred to as in leukocyte) of medium volume, white in filtrate
Cell is the leukocyte (referred to as SL) of small size, collects large, medium and small leukocyte separation suspension respectively, and conventional centrifugal sinks
Form sediment, inhale and abandon supernatant, with the large, medium and small leukocyte cell pellet of quantitative liquid shifter draws equal amounts respectively, conventional method (machinery or thin
Cellular lysate liquid) cell lysis (as used lysate of the same race, need dosage equal), take supernatant after centrifugation, then according to HIV-
1p24 antigen detection kit (euzymelinked immunosorbent assay (ELISA), inspiration bio tech ltd, Shanghai) operate, with concentration known 0pg/ml,
The p24 antigen of 0.5pg/ml, 1pg/ml, 2.5pg/ml, 5pg/ml, 20pg/ml, 40pg/ml, 80pg/ml is as comparison, minimum
Detection limit is less than 5pg/ml, measurement range 0~400pg/ml, range of linearity 0.5pg/ml~80pg/ml, and in 15min, 450nm surveys
Determining absorbance (OD), blank calibration object absorbance is not higher than 0.050, and 0pg absorbance is not higher than 0.100,1000pg/
Ml absorbance is not less than 1.000, is considered as positive as absorbance > 0.12, and testing result (table 1) illustrates, AIDS patient is not
HIV-p24 content in the leukocyte of same volume size is different, and in large, medium and small leukocyte, the average content of HIV-p24 is respectively
For 275.0pg/ml, 196.0pg/ml, 126.4pg/ml, HIV-p24 average content difference in the most large and small leukocyte
148.6pg/ml, decrease 54.4%;In large, medium and small leukocyte the total content of HIV-P24 be respectively 1375.0pg/ml,
979.9pg/ml, 632.1pg/ml, in the most large and small leukocyte, HIV-p24 total content difference 742.9pg/ml, decreases
54.3%, through statistical test, t=2.43, p < 0.05.Large volume leukocyte in AIDS patient body is described or resists through gp120
The large volume leukocyte formed after body effect contains the HIV of high level, can be by implementing technical scheme quilt
Separate and remove.
2, the checking of HIV effect removed by depurator
In order to verify that effect of HIV is removed in macrophage strain, the present invention devises easy method of testing: take sterilizing
2.5 × 300mm Westergren's blood sedimentation tube 5, draws by centrifugation macrophage strain that (1000r/min, 5min) precipitate respectively to 200mm
Scale, then draws and is incubated after 100 DEG C dissolve at 39~41 DEG C of 0.9% standby agarose C1-4B, reaches about 10mm length and carves
Degree, after putting blood sedimentation tube cooling, agarose becomes semi-solid, blood sedimentation tube inner cell can be stoped to flow out but will not stop the water of little molecule
Pass through with the material of chemical analysis etc.The acquired immune deficiency syndrome (AIDS) (AIDS) that Ling Qu Disease Control and Prevention Center and Infectious Diseases Lab Sample Storehouse preserve is suffered from
5 example blood plasma, the most about 10mL of person, before respectively taking 9mLAIDS filter, blood plasma injects blood sedimentation tube (simple purifier) upper end sky in batches
Pipe, wait flowing through the macrophage strain layer of blood sedimentation tube lower floor and after flowing out in blood sedimentation tube, collects effluent, blood after referred to as AIDS filter
Slurry.Take blood plasma after the front blood plasma of AIDS filter and filter, with MIF (MIF) ELISA detection kit (Shanghai
Hundred stamen bio tech ltd) pairing detection, by specification operates, and detection range is 0~800pg/ml, and sensitivity is
1.0pg/ml, directly can detect by an unaided eye: in reacting hole, color is the deepest under white background, and the positive is the strongest, and negative reaction is nothing
Color or the most shallow, according to the depth in color, with "+", "-" number represents.Also OD value can be surveyed: on ELISA detector, in
450nm (if developing the color with ABTS, then 410nm) place, surveys each hole OD value after returning to zero with blank control wells, if right more than the feminine gender of regulation
According to 2.1 times of OD value, it is the positive.Result such as table 1, before filter, MIF testing result is feminine gender (or because content is less than inspection in blood plasma
Survey sensitivity, blood plasma and preserve cause degraded etc. for a long time), and after filtering, in blood plasma, testing result is the positive.Illustrate that macrophage strain exists
This process creates MIF cytokine.MIF is the multi-effect egg integrating cytokine, somatomedin, hormone and enzyme characteristic
White molecule, as the effect of the regulatory factor performance central of inherent immunity and inflammatory reaction, scorching in various infection and acute and chronic
Disease property disease plays panimmunity function.Filter before and after simple depurator while MIF pairing detection making AIDS blood plasma, this
The pairing detection of HIV-1p24 has also been done in invention, and according to HIV-1p24 antigen detection kit, (euzymelinked immunosorbent assay (ELISA), Shanghai is inspired raw
Thing Science and Technology Ltd.) operation, with concentration known 0pg/ml, 0.5pg/ml, 1pg/ml, 2.5pg/ml, 5pg/ml, 20pg/ml,
The p24 antigen of 40pg/ml, 80pg/ml is less than 5pg/ml, measurement range 0~400pg/ml, line as comparison, lowest detectable limit
Property scope 0.5pg/ml~80pg/ml, in 15min, 450nm measures absorbance (OD), and blank calibration object absorbance is the highest
In 0.050,0pg absorbance is not higher than 0.100, and 1000pg/ml absorbance is not less than 1.000, the quilt as absorbance > 0.12
Being considered positive, after result (table 2) illustrates that AIDS blood plasma filters simple purifier, part HIV is swallowed by macrophage strain
Absorption, the blood plasma HIV after filtration significantly reduces, and after the 1st time filters, HIV clearance rate is 20.55%, after the 2nd time filters,
HIV clearance rate is 42.83%, and p < 0.01 has a significant effect, and illustrates that the increase HIV along with filtering number of times can be by constantly
Remove, thus reach to treat AIDS purpose.
Before and after table 1 AIDS blood plasma filters the simple purifier containing macrophage, MIF testing result is (quantitative: pg/ml)
Table 2 AIDS blood plasma filters p24 testing result (p24:pg/ml) before and after the simple purifier containing macrophage
In a word, above-mentioned simple confirmatory experiment shows, is easily fused into large volume by the peripheral blood leucocyte of HIV many
Core giant cell or many cells polymer, can be separated by blood separator and remove;And HIV free in blood plasma, can be by plasma purification
Agent (macrophage strain) is removed, and shows that with separator and depurator (agent) be the acquired immune deficiency syndrome (AIDS) biological cell immunity that critical component is constituted
Therapeutic instrument has the therapeutic efficiency significantly removing the inside and outside inhibition of HIV of hemocyte.
Claims (12)
1. the acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument for medical domain, it is characterised in that by external made susceptible HIV
Cell be formulated in, with certain concentration, the medium that favourable cell preserves, the exit made of perfusion high-biocompatibility material is arranged
The depurator of screen cloth, makes depurator and made blood and plasma separator constitute the main part of extracorporeal circulation apparatus, is used for filtering and contains
There is the HIV in the multinucleated giant cell of HIV and blood plasma.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 1, it is characterised in that described susceptible HIV's is thin
Born of the same parents include being directly separated and/or the macrophage in stem cell induction source, dendritic cell, neurogliocyte, CD4+T are thin
Born of the same parents, mononuclear cell and the granule being coated with CD4 molecule made by chemical coupling, crosslinking, affine absorption, and/or and CD4
The granule that+cell function is similar.
3. according to the arbitrary described acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument of claim 1 and 2, it is characterised in that described external
The cell phalangeal cell of made susceptible HIV can infinitely expand in co-culturing with specific composition.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 3, it is characterised in that described specific composition is energy
Make the SV40LT of cellular immortalization, hTERT, Epstein-Barr virus, oncogene, cell growth stimulant and derivant and CD4+ cell
Surface antibody.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 4, it is characterised in that described CD4+ cell table
Face antibody includes CD 3-resisting monoclonal antibody, AntiCD3 McAb/CD28 double antibody.
6. according to the arbitrary described acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument of claim 1 and 4, it is characterised in that for easily
Sense cell transduction SV40LT, hTERT gene of HIV and to cause the carrier cloning of immortalization be SV40LT/pLXSN, hTERT/
PLPCX, SV40LT/pcDNA3.1 (-) and hTERT/pLXSNneo.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 1, it is characterised in that described certain concentration refers to
The concentration of immunocyte and immune particle for swallow the concentration of the macrophage strain of HIV be 80%, for adsorbing HIV reaches
More than 95%.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 1, it is characterised in that Jie preserved for cell
Matter is containing 30% hyclone, the RPMI-1640 of 12% dimethyl sulfoxide.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 1, it is characterised in that described blood separator
Inner chamber is communicated with exocoel by the micropore on tube wall, and the aperture of described micropore is 1~250 μm, can by single blood cell but
Can not be by two and above mutual bonding or the large volume cell of fusion.
Acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument the most according to claim 9, it is characterised in that selection micropore size is
150~250 μm, 50~150 the separator of μm separate the fungus of especially big volume, spirillum and/or tumor cell;Select micropore hole
Footpath is that 15~40 μm, 8~15 μm, 5~8 μm, 3~5 mononuclear phagocyte of separator separation HIV of μm, multinuclear are big and small
Born of the same parents, many cells polymer, the particulate matter being adsorbed with HIV and/or the easy CD4+ cell by HIV.
11. acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument according to claim 1, it is characterised in that the appearance of described depurator
Amassing is 200~300ml, imports and exports and is equipped with cell screen cloth, and footpath, import department top sieve number is 800 mesh, footpath screen cloth at the bottom of exit
Mesh number is 2.0~5.0 mesh, and liquid outlet arranges the cell strainer that mesh number is 100 mesh, arranges between liquid entrance and screen cloth
The relief area of accelerating system stable circulation.
12. claim 1-11 arbitrary described acquired immune deficiency syndrome (AIDS) biological cell immunization therapy instrument answering in preparing extracorporeal circulation apparatus
With, it is characterised in that described extracorporeal circulation apparatus include one end of arterial blood line pipe (1) through heparin and blood pump (2) with contain
The blood separator (3) of waste liquid outlet (5) is connected, and blood separator (3) exports (4), blood pump (6), circulation line through blood
(7) being connected with plasma separator (8), the plasma outlet port of plasma separator (8) is through blood plasma pump (9) and blood vessel (10) with two also
The depurator (11) of connection is connected with depurator (12), and the export pipeline (13) of two depurators is thin with the blood of plasma separator (8)
Born of the same parents' export pipeline (14) confluxes through venous line (15) after converging.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610541000.1A CN106178163B (en) | 2016-07-01 | 2016-07-01 | AIDS biological cell immunization therapy instrument |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610541000.1A CN106178163B (en) | 2016-07-01 | 2016-07-01 | AIDS biological cell immunization therapy instrument |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106178163A true CN106178163A (en) | 2016-12-07 |
CN106178163B CN106178163B (en) | 2019-02-01 |
Family
ID=57473312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610541000.1A Active CN106178163B (en) | 2016-07-01 | 2016-07-01 | AIDS biological cell immunization therapy instrument |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106178163B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172907A (en) * | 2018-07-01 | 2019-01-11 | 翁炳焕 | A kind of AIDS immunoadsorption therapy instrument |
CN113528453A (en) * | 2021-07-07 | 2021-10-22 | 金宇保灵生物药品有限公司 | Immortalized pig macrophage strain and construction method and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1084216A (en) * | 1992-07-17 | 1994-03-23 | 丹拿法伯癌病研究院 | Bonded method in the target molecule cell |
WO1996028198A1 (en) * | 1995-03-13 | 1996-09-19 | Ao Forschungsinstitut Davos | An extracorporeal blood treatment apparatus and method for removal of free circulating infectious agents |
CN1146136A (en) * | 1994-02-14 | 1997-03-26 | 杰纳勒尔医疗公司 | Targeted cytolysis of HIV-infected cells by Chimeric CD4 receptor bearing cells |
US6174299B1 (en) * | 1991-09-09 | 2001-01-16 | Harvey B. Pollard | Method for treating hemophilia A and B and AIDS and devices used therein |
CN1084216C (en) * | 1996-03-26 | 2002-05-08 | 三菱重工业株式会社 | Concentrating and discharging method for wet fume-extracting desulfurizing absorption liquor raw material |
EP1621214A1 (en) * | 2000-10-20 | 2006-02-01 | Noritake Co., Limited | Material for treating harmful substance, and method and apparatus for treating harmful substance |
US20090081176A1 (en) * | 2007-09-07 | 2009-03-26 | Rudolph Maravich | Cure for the human immunodeficiency virus |
CN102631891A (en) * | 2012-04-23 | 2012-08-15 | 武汉大学 | Human immunodeficiency virus affinity adsorption column, and preparation method and uses thereof |
CN104801278A (en) * | 2015-03-29 | 2015-07-29 | 武汉瑞法医疗器械有限公司 | Preparation method of AIDS (acquired immune deficiency syndrome) virus affinity adsorbent |
CN105392888A (en) * | 2013-03-16 | 2016-03-09 | 诺华股份有限公司 | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
-
2016
- 2016-07-01 CN CN201610541000.1A patent/CN106178163B/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6174299B1 (en) * | 1991-09-09 | 2001-01-16 | Harvey B. Pollard | Method for treating hemophilia A and B and AIDS and devices used therein |
CN1084216A (en) * | 1992-07-17 | 1994-03-23 | 丹拿法伯癌病研究院 | Bonded method in the target molecule cell |
CN1146136A (en) * | 1994-02-14 | 1997-03-26 | 杰纳勒尔医疗公司 | Targeted cytolysis of HIV-infected cells by Chimeric CD4 receptor bearing cells |
WO1996028198A1 (en) * | 1995-03-13 | 1996-09-19 | Ao Forschungsinstitut Davos | An extracorporeal blood treatment apparatus and method for removal of free circulating infectious agents |
CN1084216C (en) * | 1996-03-26 | 2002-05-08 | 三菱重工业株式会社 | Concentrating and discharging method for wet fume-extracting desulfurizing absorption liquor raw material |
EP1621214A1 (en) * | 2000-10-20 | 2006-02-01 | Noritake Co., Limited | Material for treating harmful substance, and method and apparatus for treating harmful substance |
US20090081176A1 (en) * | 2007-09-07 | 2009-03-26 | Rudolph Maravich | Cure for the human immunodeficiency virus |
CN102631891A (en) * | 2012-04-23 | 2012-08-15 | 武汉大学 | Human immunodeficiency virus affinity adsorption column, and preparation method and uses thereof |
CN105392888A (en) * | 2013-03-16 | 2016-03-09 | 诺华股份有限公司 | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor |
CN104801278A (en) * | 2015-03-29 | 2015-07-29 | 武汉瑞法医疗器械有限公司 | Preparation method of AIDS (acquired immune deficiency syndrome) virus affinity adsorbent |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172907A (en) * | 2018-07-01 | 2019-01-11 | 翁炳焕 | A kind of AIDS immunoadsorption therapy instrument |
CN113528453A (en) * | 2021-07-07 | 2021-10-22 | 金宇保灵生物药品有限公司 | Immortalized pig macrophage strain and construction method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN106178163B (en) | 2019-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4988559B2 (en) | Cell preparation | |
CN106267413B (en) | AIDS plasma purification device | |
CN106267425A (en) | AIDS immunoadsorption therapy instrument | |
CN114209814B (en) | Application of TNFSF15 protein in promoting differentiation of bone marrow stem cells into macrophages and expansion | |
CN106178163B (en) | AIDS biological cell immunization therapy instrument | |
CN106267410B (en) | HIV infection cell separator | |
CN106267419B (en) | HIV immunologic purging device | |
CN106039448B (en) | AIDS cell adsorbing therapy instrument | |
CN106075626B (en) | A kind of AIDS blood purifying therapeutical instrument | |
CN106267416B (en) | AIDS therapeutic equipment | |
CN106166313B (en) | A kind of AIDS pregnant woman blood clarifier | |
CN106267415B (en) | AIDS purification treatment instrument | |
CN106110425B (en) | AIDS plasma purification therapeutic equipment | |
CN106267417B (en) | AIDS therapeutic response device | |
CN106110426B (en) | AIDS immunization therapy instrument | |
CN106267409B (en) | AIDS biological therapy reactor | |
CN106178162B (en) | Treating AIDS organelle | |
CN106267414B (en) | AIDS immunologic purging device | |
CN106267406B (en) | AIDS blood purification | |
CN106267411B (en) | AIDS toxin expelling therapeutic equipment | |
CN106267424B (en) | AIDS immune cell therapy instrument | |
CN106497883A (en) | A kind of human umbilical cord mesenchymal stem cells of stably expression antioncogene REIC/Dkk3 and its construction method and application | |
CN106267420B (en) | HIV phagocyte device | |
CN106267412B (en) | AIDS immunologic purging instrument | |
CN106267404B (en) | AIDS biological cell therapeutical instrument |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200824 Address after: 310006 No. 1, bachelor Road, Zhejiang, Hangzhou Co-patentee after: Shu Lan (Hangzhou) Hospital Ltd. Patentee after: WOMEN'S HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG University Address before: The 317300 Ring Road Zhejiang County of Xianju province to the north, Xianju County Hospital Patentee before: Weng Binghuan |
|
TR01 | Transfer of patent right |